A sprayable Acid-Oxidizing solution containing hypochlorous acid (AOS2020) efficiently and safely inactivates SARS-Cov-2: a new potential solution for upper respiratory tract hygiene

Abstract

Introduction To eliminate the COVID-19 pandemic, the transmission of the virus SARS-CoV-2 among the population needs to be blocked and/or at least reduced. Upper respiratory tract viral loads are highest in the early stages of the disease, and high loads are associated with higher mortality rates. This study aims to evaluate the virucidal efficacy of AOS2020, a novel sprayable Acid-Oxidizing solution containing pure and stable hypochlorous acid (HClO), on human coronavirus SARS-Cov-2 in vitro, and the tolerability profile on nasal and oral mucosa suggesting to be a potential solution for upper respiratory hygiene. Method Virucidal assays and intranasal and oral irritation tests were undertaken in accordance with relevant national and international guidance and methods. Results In pre-clinical tests, the AOS2020, showed > 99.8% virucidal efficacy in < 1 min against SARS-Cov-2. The safety profile testing on both the nasal and oral mucosa indicates that AOS2020 is non-irritant. Conclusion These initial results indicate that this product has the potential treatment to reduce viral load in the upper respiratory tract.

Topical hypochlorous acid (HOCl) blocks inflammatory gene expression and tumorigenic progression in UV-exposed SKH-1 high risk mouse skin

“…Remarkably, HOCl-induced oxidation also represents the mechanistic basis of freshwater preservation relevant to public drinking water safety and pool disinfection [ [10] , [11] , [12] , [13] , [14] ]. In addition, HOCl consumer products are used on a global scale for surface and skin disinfection targeting viruses, bacteria, and other microbes, a topic of contemporary relevance in the context of the unfolding COVID-19 pandemic [ 15 , 22 , 23 ].…”

“…Interestingly, in addition to endogenous and environmental sources, skin HOCl exposure also occurs through application of topical disinfectants employed worldwide as clinical and consumer products, a preventive use with particular relevance to the ongoing COVID-19 pandemic [ [21] , [22] , [23] ]. Remarkably, topical HOCl-based therapeutics optimized for sustained release are now serving as FDA-approved drugs for wound management, atopic dermatitis, pruritus, and psoriasis [ 24 , 25 ].…”

A relação da condição bucal com a transmissibilidade e o agravamento da COVID-19: uma revisão integrativa / The relationship between oral condition and transmissibility and aggravation of COVID-19: an integrative review

“…A antissepsia química, por meio de bochechos com atividade antimicrobiana, é defendida e usada em várias situações clínicas, diminuindo, consequentemente, o risco de transmissão da doença (O'DONNELL et al, 2020;MEISTER et al, 2020;ANDERSON et al, 2020). Frente a isso, pesquisas tem mostrado uma potencialidade de enxaguantes bucais para o combate da transmissão do SARS-Cov-2, principalmente produtos contendo cloreto de desqualínio, cloreto de benzalcônio, iodopovidona, etanol, óleos essenciais, ácido hipocloroso e carragenina servirem de combate ao referido microrganismo (MEISTER et al, 2020;ANDERSON et al, 2020;GIARRATANA et al, 2021;SCHÜTZ et al, 2021).…”

“…A investigação de Giarratana et al (2021) revelou que em testes pré-clínicos em animais, o AOS2020, uma nova solução oxidante de ácido pulverizável contendo ácido hipocloroso (HClO) puro e estável, tem alta eficácia viricida contra SARS-Cov-2, em um período menor que 1 minuto. O teste de perfil de segurança na mucosa nasal e oral indica que a substância testada não é irritante.…”

COVID-19 Patient Psychological Pain Factors

“…If the infected cells signal help, T cells and natural killer cells respond and kill the infected cells. Our immune system attacks cells infected by the virus, which may lead to many symptoms of colds, influenza and fatal diseases (Giarratana et al, 2021 ). That's what makes us sick.…”